Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy

Area of Science:

• Immunology
• Cellular Therapy
• Gene Therapy

Background:

• Chimeric antigen receptors (CARs) integrate antibody-based antigen binding with T-cell signaling, overcoming MHC restriction for broader cellular therapy applications.
• CAR T-cells provide targeted tumor recognition, active trafficking, in vivo expansion, and long-term persistence, surpassing monoclonal antibody limitations.
• Gene transfer enables incorporating tumor immune evasion countermeasures and safety features into CAR T-cells.

Purpose of the Study:

• To review the structure and evolution of CARs, from first to later generations.
• To discuss methods for genetically modifying immune cells to express CARs, including viral and non-viral approaches.
• To explore strategies for enhancing the in vivo persistence and functionality of CAR-engineered immune cells.

Main Methods:

• Examination of CAR T-cell generation, including retroviral and non-retroviral transduction.
• Review of preclinical models and clinical studies targeting tumor-associated antigens with CAR T-cells.
• Analysis of safety considerations and mitigation strategies for CAR gene transfer.

Main Results:

• First and later generation CARs demonstrate advantages over other immunotherapies.
• Various CAR T-cell applications in preclinical and clinical settings have been explored.
• Safety profiles and management strategies for CAR T-cell therapies are being refined.

Conclusions:

• CAR-modified T-cells are poised to significantly advance cancer treatment.
• The role of CAR T-cells is expanding to include chronic infections and autoimmune diseases.
• Progress in immunology, genetics, and cell processing underpins the growing importance of CAR T-cell therapy.